ImageneBio (IMA) Net Cash Flow (2020 - 2025)

ImageneBio has disclosed Net Cash Flow across 6 years of filings, most recently posting -$64.0 million for Q3 2025.

• Net Cash Flow for Q3 2025 came in at -$64.0 million, down 192.98% year-over-year; the trailing twelve-month figure through Dec 2025 was -$45.0 million (up 44.32% YoY), and the FY2024 annual result was -$80.9 million, down 233.99% from the prior year.
• Net Cash Flow came in at -$64.0 million for Q3 2025 at ImageneBio, down from $26.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $118.5 million in Q1 2021 to a low of -$185.3 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$7.2 million (2025), against an average of -$10.8 million.
• Across the five-year window, Net Cash Flow jumped 1288.76% in 2021 and sank 5256.69% in 2024, its largest moves.
• ImageneBio's Net Cash Flow stood at -$13.7 million in 2021, then jumped by 47.71% to -$7.2 million in 2022, then jumped by 80.67% to -$1.4 million in 2023, then tumbled by 5256.69% to -$74.1 million in 2024, then rose by 13.65% to -$64.0 million in 2025.
• The last three Net Cash Flow figures came in at -$64.0 million (Q3 2025), $26.1 million (Q2 2025), and -$7.2 million (Q1 2025), per Business Quant data.